Accueil   Diary - News   All news Synthelis and MAbSilico sign a commercial agreement

Synthelis and MAbSilico sign a commercial agreement

 

Synthelis and MAbSilico sign a commercial agreement to promote a joint service offering.

 

As of June 21, 2018, Synthelis and MAbSilico combine their know-how and thus capitalize on their respective technology in developing a joint offer through a commercial agreement, responding to the needs of their customers.

 

This offer combines the cutting-edge expertise of two recognized players in their respective domain: MAbSilico with its in silico method to characterize antibodies at their early stage of development and Synthelis, for its cell-free patented technology. 

 

Indeed, MAbSilico proposes services for the characterization of therapeutic antibodies with a wide scope from epitope mapping (MAbTope), to cross-reactivity evaluation (MAbCross) as well as alternative antibody identification (MAbSubstitute) and target identification (MAbTarget). Then, Synthelis can them quickly express the targets or the antibodies using the cell-free technology to validate the properties modelled in silico.

 

Vincent Puard, CEO of MAbSilico says: “This first commercial partnership is very exciting for MAbSilico after only 9 months of incorporation. We are very happy to sign with a French company which offers a unique technology for protein production. It will help our clients’ projects and the development of new services for antibody characterization. “

 

And Bruno Tillier, President of Synthelis to add: “We are very happy to sign this new partnership with MAbSilico which is such an innovative and dynamic company. The power of Biocomputing using algorithms and big data, fits perfectly with the proven effectiveness of our cell-free technology. This combination guarantees our clients added value to accelerate, secure and increase the development of their antibody development projects.”

 

At the end, thanks to the combination of the in silico method validated by the experimental one, Synthelis and MAbSilico offer a fast and reliable solution to help their clients overcome their main hurdles and lead their projects serenely.

 

 

Read the press release